DSIP (Delta Sleep Inducing Peptide)

PEPTIDES+ MEMBERS ONLY

INDICATIONS FOR USE

Delta Sleep-Inducing Peptide (DSIP) is an experimental therapy primarily researched for its potential to improve sleep quality, promote deeper and more restorative sleep cycles, and regulate circadian rhythms. It has also been studied for its potential to reduce stress, enhance recovery, and alleviate certain types of chronic pain, such as those associated with fibromyalgia.

ROUTE OF ADMINISTRATION

  • Subcutaneous injection

FORMULATIONS AND PRICING

FormulationPrice
9mg multi-dose vial (3mg/mL x 3mL)$95

COMMON INITIAL DOSING REGIMENS

  • Initial dosing commonly ranges from 100 to 300 micrograms injected subcutaneously, typically administered in the evening before sleep. Dosages may be adjusted based on individual response and tolerance, with some protocols suggesting daily use, while others recommend intermittent schedules (e.g., 3–5 times weekly).

MECHANISM OF ACTION

  • DSIP is a neuropeptide that modulates the sleep-wake cycle by interacting with the central nervous system, particularly regions involved in circadian rhythm regulation. It is thought to promote sleep by enhancing slow-wave (delta) sleep, reducing arousal levels, and regulating levels of sleep-promoting hormones like melatonin. DSIP also modulates stress response pathways, including those mediated by corticotropin-releasing factor (CRF), which may contribute to its calming effects.

COMMON SIDE EFFECTS

  • Mild and uncommon due to its limited systemic effects. Reported side effects include fatigue or lethargy upon waking if the dose is too high or administered at the wrong time, injection site reactions, such as redness or mild irritation, and headache or dizziness in rare cases.

CONTRAINDICATIONS

  • Absolute: Hypersensitivity to DSIP or any of its components.'

  • Relative: Caution is advised in individuals with severe psychiatric conditions, untreated sleep disorders (e.g., severe obstructive sleep apnea), or those on medications affecting the CNS. Long-term safety data is limited, so use in individuals with significant medical conditions or during pregnancy/lactation should be undertaken with caution.

MORE INFORMATION

  • FDA Safety Data Sheet not available (experimental peptide therapy)

  • Pollard BJ, Pomfrett CJ. Delta sleep-inducing peptide. Eur J Anaesthesiol. 2001 [PubMed link]

  • Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986 [PubMed link]

  • Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984 [PubMed link]

  • Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992 [PubMed link]

  • Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987 [PubMed link]

  • Schneider-Helmert D, Graf M, Schoenenberger GA. Synthetic delta-sleep-inducing peptide improves sleep in insomniacs. Lancet. 1981 [PubMed link]

  • Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981 [PubMed link]

  • Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981 [PubMed link]